(Total Views: 360)
Posted On: 10/02/2020 3:23:48 PM
Post# of 72
From another board:
Email content from Chris Reinhard
As a follow-up to my emails sent on September 4 and September 14, and as set forth in the documents previously provided (that included our Form 8-K SEC submission), and further articulated in my referenced two previous emails, there has been no change to our business strategy and focus. Our business strategy includes: (1) fully satisfy our SEC compliance obligations, and (2) complete the necessary FDA study to enable Gene Biotherapeutics to seek registration to market and sell our lead product candidate Generx Ad5FGF-4 angiogenic gene therapy, for patients with refractory angina due to advanced coronary disease, first in the United States and then internationally. Many thanks for investment and patience as we advance forward. Regards, Chris
Email content from Chris Reinhard
As a follow-up to my emails sent on September 4 and September 14, and as set forth in the documents previously provided (that included our Form 8-K SEC submission), and further articulated in my referenced two previous emails, there has been no change to our business strategy and focus. Our business strategy includes: (1) fully satisfy our SEC compliance obligations, and (2) complete the necessary FDA study to enable Gene Biotherapeutics to seek registration to market and sell our lead product candidate Generx Ad5FGF-4 angiogenic gene therapy, for patients with refractory angina due to advanced coronary disease, first in the United States and then internationally. Many thanks for investment and patience as we advance forward. Regards, Chris
(0)
(0)
